Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study to Evaluate Effectiveness, Safety and Satisfaction Level of Zastaprazan (JAQBO®) Under Daily Treatment for Patients With Erosive Gastroesophageal Reflux Disease

NCT06952855 is registered in ClinicalTrials.gov with Jeil Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06952855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06952855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study to Evaluate Effectiveness, Safety and Satisfaction Level of Zastaprazan (JAQBO®) Under Daily Treatment for Patients With Erosive Gastroesophageal Reflux Disease
Lead sponsor
Jeil Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
November 1, 2024
Completion date
April 23, 2025
Enrollment
5,536 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acid regurgitation, erosive reflux disease, heartburn